ARTICLE | Deals
BMS adds new mechanism to solid tumor pipeline via ADC deal with Eisai
BMS-Eisai collaboration follows an active year in ADC dealmaking
June 18, 2021 9:08 PM UTC
In the latest example of antibody-drug conjugates attracting high-value deals, BMS is adding anti-FOLR1 antibody-drug conjugate MORAb-202 to its pipeline through a $650 million collaboration with Eisai.
The announcement led Eisai Co. Ltd. (Tokyo:4523) to an intraday 52-week high of ¥12,635 during Friday’s session, continuing an upward trend kicked off by FDA’s accelerated approval of Aduhelm aducanumab last Monday...